Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025)

Cue Biopharma's Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $80000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 20.79% year-over-year to $80000.0; the TTM value through Sep 2025 reached $378000.0, down 8.25%, while the annual FY2024 figure was $397000.0, 28.6% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $80000.0 at Cue Biopharma, down from $99000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $318000.0 in Q1 2021 and bottomed at $80000.0 in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $136000.0 (2023), against an average of $179613.8.
  • The largest annual shift saw Depreciation & Amortization (CF) grew 22.17% in 2021 before it tumbled 44.33% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $309662.0 in 2021, then plummeted by 34.44% to $203000.0 in 2022, then crashed by 44.33% to $113000.0 in 2023, then dropped by 13.27% to $98000.0 in 2024, then decreased by 18.37% to $80000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Depreciation & Amortization (CF) are $80000.0 (Q3 2025), $99000.0 (Q2 2025), and $101000.0 (Q1 2025).